Daptomycin for Injection: Clinical Trials

3 trials of Daptomycin for Injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 recruiting. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Terminated 2, Recruiting 1

Follow Daptomycin for Injection: new trials by email Literature Review of Daptomycin for Injection trials Research Report on Daptomycin for Injection

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Phase 4RecruitingTodd C. Lee MD MPH FIDSA3002024-11-142026-09-09
Phase 4 Efficacy and Safety Study of CubicinĀ® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
daptomycin, daptomycin and gentamicin - Infective Endocarditis
Phase 4TerminatedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)242009-02-132021-02-02
Cubicin(R) for Complicated Post-surgical Wound Infections
daptomycin - Wound Infections
Phase 4TerminatedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)692004-06-012017-08-30

Conditions studied

Bacteremia (1)  ·  Endocarditis (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Staphylococcal Infections (1)  ·  Wound Infection (1)

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)  ·  Todd C. Lee MD MPH FIDSA (1)

Countries

Australia (1)  ·  Canada (1)  ·  New Zealand (1)  ·  United States (1)

Top investigators

Paula Bokesch, M.D. (1)  ·  Todd C Lee, MD MPH FIDSA (1)

NIH funding

2025 (1)